In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

An Interview with Simon Stertzer, MD: Angioplasty Pioneer

Executive Summary

The physician who performed the first US angioplasty and helped launch the most successful stent start-up discusses interventional cardiology--past, present and future.

You may also be interested in...



More from the Device Innovators' Workbench

Interviews with medical device inventors/entrepreneurs Rodney Perkins, MD, and Mir Imran, discussing their successes, such as Collagen and PercuSurge, and the ones that didn't make it.

John Simpson: Reluctant Entrepreneur

John Simpson never set out to be a physician and still does not consider himself a businessman; yet he is a leading interventional cardiologist and has launched more than a half dozen successful device companies. Simpson takes pride in building successful teams, enabling him to delegate the engineering and business responsibilities to others, while focusing on what he does best: figuring out how to better treat the patient. He is perhaps best known for developing over-the-wire angioplasty through his first company, ACS, and has followed that with companies involved with ultrasound (CVIS), atherectomy (DVI and Fox Hollow), vascular closure (Perclose), and chronic total occlusions (LuMend). Simpson remains iconoclastic when it comes to patient care issues. So although angioplasty is where he made his name, he remains suspicious of stents and hopes through his current venture, Fox Hollow, to minimize their use.

Eyeing Agility, Astellas Expands Digital Transformation Initiative

Soon-to-start digital transformation initiatives at the major Japanese pharma firm will focus on in-housing of IT systems and company-wide enhancement of AI/data analytics skills.

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

IV002371

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel